For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $35.06 down -9.80% from its previous closing price of $38.87. In other words, the price has decreased by -$9.80 from its previous closing price. On the day, 1.32 million shares were traded.
Ratios:
For a deeper understanding of Ultragenyx Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.37. In the meantime, Its Debt-to-Equity ratio is 3.56 whereas as Long-Term Debt/Eq ratio is at 3.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 05 ’25 when Crombez Eric sold 520 shares for $39.24 per share. The transaction valued at 20,405 led to the insider holds 71,530 shares of the business.
Crombez Eric sold 242 shares of RARE for $8,497 on Apr 21 ’25. The EVP and Chief Medical Officer now owns 71,680 shares after completing the transaction at $35.11 per share. On Mar 06 ’25, another insider, Horn Howard, who serves as the Chief Financial Officer of the company, sold 1,785 shares for $40.40 each. As a result, the insider received 72,114 and left with 106,169 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 5.88 while its Price-to-Book (P/B) ratio in mrq is 12.69.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $29.59. The 50-Day Moving Average of the stock is -6.89%, while the 200-Day Moving Average is calculated to be -24.36%.
Shares Statistics:
A total of 92.41M shares are outstanding, with a floating share count of 87.94M. Insiders hold about 6.35% of the company’s shares, while institutions hold 93.82% stake in the company.
